Zydus Cadila and Sandoz generics approvals in North America

Generics/News | Posted 31/05/2021 post-comment0 Post your comment

In April 2021, Zydus Cadila received final approval from the US Food and Drug Administration to market its ibrutinib and macitentan generics. In addition, in May 2021, Sandoz Canada announced the launch of their pirfenidone, a generic version of F. Hoffmann-La Roche’s Esbriet®.

27 MD002442

US approvals
Following the recent approvals, Indian multinational, Zydus Cadila will now launch ibrutinib capsules (70 mg and 140 mg) and macitentan tablets (10 mg).

Ibrutinib is a kinase inhibitor and is used to treat certain cancers, including mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia. Zydus was the first abbreviated new drug application (ANDA) applicant to submit a substantially complete ANDA with a paragraph IV certification for the 70 mg product and will thus receive 180 days of generic drug exclusivity for this product. For the ibrutinib capsules, 140 mg, they will have 180-days of shared generic drug exclusivity.

Macitentan is an endothelin receptor antagonist used to manage the symptoms of pulmonary arterial hypertension. As one of the first ANDA applicants, Zydus is also eligible for 180 days of shared generic drug exclusivity for its macitentan tablets, 10 mg.

Canadian approval
Sandoz is the first manufacturer to launch a generic pirfenidone product. This is indicated in the treatment for idiopathic pulmonary fibrosis in adults. The product will now mainly be sold at the community pharmacy level and will be available as 267 mg tablets in bottles of 21 or 270 tablets, and as 801 mg in bottles of 90 tablets.

Related articles
Posaconazole silodosin and droxidopa generics from Lupin and Sandoz

COVID-19 vaccine and FDA approvals for Zydus Cadila

Zydus gets FDA approval for skin, heart and acid reflux generics


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010